Azitra, Inc.

Azitra, Inc. is an early-stage clinical biopharmaceutical company dedicated to developing innovative therapies for precision dermatology. Headquartered in Branford, Connecticut, the company leverages the power of the human microbiome and cutting-edge genetic engineering to address various skin conditions and diseases. Founded in 2014, Azitra aims to create novel treatments by harnessing beneficial properties of skin commensal bacteria.

Azitra's core technology platform includes a proprietary microbial library containing approximately 1,500 unique bacterial strains, with over 900 strains of Staphylococcus epidermidis, which are screened using artificial intelligence and machine learning for therapeutic characteristics. The company's pipeline features several product candidates: ATR-12, a genetically modified S. epidermidis in Phase 1b/2a clinical trials for Netherton syndrome; ATR-04, another genetically modified S. epidermidis with FDA Fast Track designation, in Phase 1/2 clinical trials for papulopustular rash in cancer patients undergoing EGFR inhibitor therapy; and ATR-01, an engineered recombinant human filaggrin protein in the IND-enabling phase for ichthyosis vulgaris. Azitra also has a joint development agreement with Bayer focused on natural skincare products.

Led by President and CEO Francisco Salva and Cofounder and COO Travis Whitfill, Azitra is actively advancing its clinical programs. Recent developments include a poster presentation in April 2026 highlighting the ATR-01 program and the pricing of a private placement financing in March 2026. The company also received a notice of non-compliance from NYSE American in March 2026 regarding minimum stockholders' equity, but its compliance plan was accepted, with a deadline of April 1, 2027, to regain compliance. In February 2026, Azitra announced the MD Anderson Cancer Center as a clinical site for its ATR-04 trial.